News stories about Portola Pharmaceuticals (NASDAQ:PTLA) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Portola Pharmaceuticals earned a daily sentiment score of 0.10 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 45.7070958274566 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:
- Portola Pharmaceuticals (PTLA) to Release Quarterly Earnings on Wednesday (americanbankingnews.com)
- This Morning’s Technical Outlook on Biotech Stocks — Portola Pharma, Protalix BioTherapeutics, Radius Health, and Regulus Therapeutics (medindia.net)
- Q1 2018 EPS Estimates for Portola Pharmaceuticals Inc (PTLA) Cut by Oppenheimer (americanbankingnews.com)
- Portola Pharmaceuticals Inc Expected to Earn FY2021 Earnings of $5.72 Per Share (PTLA) (americanbankingnews.com)
Shares of Portola Pharmaceuticals (PTLA) traded up $0.72 on Thursday, reaching $47.98. 251,145 shares of the company’s stock were exchanged, compared to its average volume of 891,944. The company has a market capitalization of $3,130.00, a PE ratio of -11.11 and a beta of 1.18. The company has a current ratio of 8.31, a quick ratio of 8.31 and a debt-to-equity ratio of 0.24. Portola Pharmaceuticals has a 1 year low of $29.50 and a 1 year high of $67.10.
In other news, Director Henry Ward Wolff sold 12,000 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $47.00, for a total transaction of $564,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 5.50% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece of content was first published by Week Herald and is owned by of Week Herald. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://weekherald.com/2018/02/15/portola-pharmaceuticals-ptla-getting-somewhat-positive-news-coverage-report-finds.html.
Portola Pharmaceuticals Company Profile
Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.